BASF and Dyadic Enter Into Research Agreement

BASF and Dyadic International, Inc. have announced that the two Companies have entered into a non-exclusive worldwide research and license agreement.

Under the terms of the agreement, BASF will be able to use Dyadic’s patented and proprietary C1 platform technology to develop, produce, distribute and sell industrial enzymes in certain fields for a variety of applications.

BASF will fund research and development at Dyadic’s research lab in The Netherlands. In addition to this funding, BASF has agreed to pay Dyadic a $6 million upfront license fee, and certain research and commercial milestone fees, as well as royalties upon commercialization.

“Dyadic’s C1 technology will strengthen BASF’s position in the industrial enzyme industry,” said Dr. Carsten Sieden, Senior Vice President Fine Chemicals and Biocatalysis Research, BASF. “We expect this license agreement with Dyadic to result in promising long-term opportunities.”

Dyadic’s President and Chief Executive Officer, Mark Emalfarb, stated, “Empowering BASF, the world’s leading chemical company, with our C1 technology provides them with access to a commercially-proven industrial enzyme production platform. In using its vast resources to develop, manufacture and sell new products from the C1 platform, BASF will have business opportunities for a variety of markets, including animal and human nutrition. This transaction will have long-lasting effects on the industrial enzyme businesses of both Dyadic and BASF.”

Emalfarb concluded, “Dyadic looks forward to working with BASF and utilizing our C1 technology for the expression of next-generation enzyme products for a range of applications. This collaboration is yet another example of Dyadic’s ability to leverage our technologies in a variety of industries.”